Baker BROS. Advisors LP boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 8.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,258,402 shares of the biopharmaceutical company's stock after buying an additional 260,630 shares during the quarter. Baker BROS. Advisors LP owned about 2.86% of Fate Therapeutics worth $5,376,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Intech Investment Management LLC increased its holdings in Fate Therapeutics by 27.5% during the 4th quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company's stock worth $65,000 after purchasing an additional 8,497 shares in the last quarter. SG Americas Securities LLC increased its position in Fate Therapeutics by 30.6% during the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 10,511 shares during the period. American Century Companies Inc. raised its position in shares of Fate Therapeutics by 6.6% in the fourth quarter. American Century Companies Inc. now owns 197,704 shares of the biopharmaceutical company's stock valued at $326,000 after buying an additional 12,295 shares in the last quarter. Franklin Resources Inc. increased its holdings in Fate Therapeutics by 9.6% in the 4th quarter. Franklin Resources Inc. now owns 165,353 shares of the biopharmaceutical company's stock valued at $273,000 after buying an additional 14,532 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Fate Therapeutics by 4.4% during the 4th quarter. Renaissance Technologies LLC now owns 378,619 shares of the biopharmaceutical company's stock worth $625,000 after buying an additional 16,000 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors.
Fate Therapeutics Trading Up 1.9 %
Shares of NASDAQ FATE traded up $0.02 during trading hours on Friday, hitting $1.05. 1,575,725 shares of the company traded hands, compared to its average volume of 2,268,807. The company's 50 day moving average price is $1.01 and its 200 day moving average price is $1.59. The stock has a market capitalization of $120.33 million, a price-to-earnings ratio of -0.64 and a beta of 2.32. Fate Therapeutics, Inc. has a 12 month low of $0.66 and a 12 month high of $5.92.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The company had revenue of $1.86 million during the quarter, compared to analyst estimates of $1.57 million. Equities analysts anticipate that Fate Therapeutics, Inc. will post -1.63 EPS for the current year.
Analyst Upgrades and Downgrades
FATE has been the topic of several recent research reports. StockNews.com downgraded Fate Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, March 11th. Stifel Nicolaus dropped their target price on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research note on Thursday, March 6th. Wedbush restated a "neutral" rating and set a $5.00 target price on shares of Fate Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company decreased their price objective on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Fate Therapeutics currently has an average rating of "Hold" and a consensus price target of $5.43.
Check Out Our Latest Analysis on FATE
Fate Therapeutics Profile
(
Free Report)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Further Reading
Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
